Intellia Therapeutics director resigns
Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion
Global M&A by the Numbers: Q2 2022
Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms
Infographic 2022 Top Tech Trends Shaping Corporations
Moncef Slaoui resigned as a board member of Intellia Therapeutics Inc. due to a conflict of interest, effective Aug. 7.
Slaoui was added to the board in July. His decision to resign did not result from any disagreement with the company on any matter relating to its operations, policies or practices.